Home | Site Map | About | Contact 
  The scientific approach to weight loss and maintenance. Indepenent, hype-free research.
 
Weight Loss Guide
 Weight Loss Basics
 Diets & Dieting
 Drug Therapy
 Supplements
 Weight Loss Surgery
 Tools & Calculators
 
News & Research
 Weight Loss News
 Published Studies
   > Drugs
   > Diets
   > Supplements
   > Surgery
   > Lifestyle
 Clinical Trials
 
 
 
 
 
 
 
   
You are here: Published Weight Loss Studies >

National trends in antiobesity medication use.

Author: Stafford RS, Radley DC

Author affiliation: Stanford Center for Research in Disease Prevention, 1000 Welch Road, Palo Alto, CA 94304, USA. rstafford@stanford.edu

Publication date & source: 2003.05.12, Arch Intern Med., 163(9):1046-50.

Publication type: Research Support, Non-U.S. Gov't ; Research Support, U.S. Gov't, P.H.S.

BACKGROUND: The use of medications to treat obesity remains controversial. Our goal was to assess national trends in antiobesity medication use with a focus on patterns surrounding the 1997 removal of antiobesity drugs from the market. METHODS: Using a serial cross-sectional study design, we analyzed a nationally representative sample of US office-based physician visits from 1991 to 2002. Data come from the IMS HEALTH National Disease and Therapeutic Index. These data include a sample of 13 452 patient visits for which a diagnosis of clinical obesity was made, with annual visits ranging from 666 in 1994 to 1854 in 1996. The unit of analysis is the patient visit, while the primary outcome measures are the annual and quarterly number of antiobesity drug mentions for clinically obese patients. RESULTS: At its peak in the second quarter of 1997, 2.5 million Americans were taking antiobesity medications, a 4-fold increase over the prior 2 years. Although antiobesity medication use diminished following the market exit of fenfluramine hydrochloride and dexfenfluramine hydrochloride, current levels of use remain above those in the early 1990s. Phentermine has consistently been the most common antiobesity medication. In 2002, an annualized 1.2 million mentions of phentermine use were noted (31% of drug-treated obese patients). Newly released medications, orlistat (0.6 million) and sibutramine hydrochloride (0.4 million), were used less often. Most antiobesity medication use occurs in patients without other reported medical conditions. CONCLUSIONS: Use of antiobesity medications increased rapidly with public and professional interest in fenfluramine-phentermine (fen-phen) combination therapy. Despite reports of adverse outcomes associated with fenfluramine agents (fen-phen and dexfenfluramine), the use of these medication therapies did not diminish until soon before their removal from the market in 1997.



Indexes of Weight Loss Research Abstracts
Weight Loss Drugs
Weight Loss Diets
Supplements
Bariatric Surgery
Lifestyle

     
-- advertisements --


Copyright © 2006 by Weight-Loss-Science.com
All inormation is for education purposes only and should not be considered as a medical advice.